SCHEMBL3013337

SCHEMBL3013337

COc1ccc(OC)c(S(=O)(=O)N2CCN(c3nc(Cc4c(C)cc(C)cc4C)cs3)CC2)c1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
MAPT P10636 2/20 0.56
RECQL P46063 2/20 0.56
KMT2A Q03164 4/20 0.52
L3MBTL1 Q9Y468 3/20 0.50
USP2 O75604 3/20 0.50
HTT P42858 2/20 0.50
LMNA P02545 1/20 0.50
MAPK1 P28482 1/20 0.50
KDM4E B2RXH2 1/20 0.49
GAA P10253 2/20 0.46
HSD17B10 Q99714 2/20 0.46
HPGD P15428 1/20 0.46
NPSR1 Q6W5P4 1/20 0.43
NPC1 O15118 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3647462 0.94 ALDH1A1 (0.50) ALDH1A1MAPTRECQLKMT2AL3MBTL1
SCHEMBL3013872 0.93 MAPT (0.47) ALDH1A1MAPTRECQLKMT2AL3MBTL1
SCHEMBL3014655 0.93 ALDH1A1 (0.64) ALDH1A1MAPTRECQLKMT2AL3MBTL1
SCHEMBL3014984 0.90 MAPT (0.50) ALDH1A1MAPTRECQLKMT2AUSP2
SCHEMBL3013604 0.90 GAA (0.50) ALDH1A1MAPTRECQLKMT2AL3MBTL1
SCHEMBL3008503 0.90 ALDH1A1 (0.55) ALDH1A1MAPTRECQLKMT2AL3MBTL1
SCHEMBL3011303 0.88 ALDH1A1 (0.55) ALDH1A1MAPTRECQLKMT2AL3MBTL1
SCHEMBL3017986 0.88 ALDH1A1 (0.55) ALDH1A1MAPTRECQLKMT2AL3MBTL1
SCHEMBL3002250 0.87 ALDH1A1 (0.55) ALDH1A1MAPTRECQLKMT2AL3MBTL1
SCHEMBL3012014 0.87 ALDH1A1 (0.56) ALDH1A1MAPTRECQLKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885MAPT 18/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.